Clinical trial Recruiting at 1 site Observational Ages 18 and up

Echocardiographic evaluation of cardiac amyloidosis

Official title: Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study

Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05760287 · Data updated 2026-11-12

This study is testing new heart imaging techniques to see if they can help tell cardiac amyloidosis apart from other heart problems and check how well tafamidis treatment can improve heart damage in patients.

More Cardiac Amyloidosis trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment255 (estimated)
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Academic / other
Locations1 site (Roma, RM)
StatusRecruiting
StartedDecember 9, 2022
Main results expectedDecember 2, 2030
Study endsFebruary 2, 2031
Registry record updatedSeptember 4, 2026
Trial IDNCT05760287 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients diagnosed with cardiac amyloidosis who meet the inclusion criteria set by the European Society of Cardiology.

Probably not a fit

Patients who do not have cardiac amyloidosis or those who decline participation will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with cardiac amyloidosis at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. It aims to utilize advanced echocardiographic techniques, including two- and three-dimensional speckle-tracking analysis, to differentiate cardiac amyloidosis from other similar heart conditions. Additionally, the study will assess the reversibility of myocardial damage in response to tafamidis treatment and explore new echocardiographic predictors of adverse cardiovascular outcomes.

Why it matters

Potential benefit: If successful, this study could enhance the diagnostic accuracy and treatment monitoring for patients with cardiac amyloidosis.

How similar studies have gone: While this approach is observational, similar studies utilizing advanced echocardiographic techniques have shown promise in improving diagnostic capabilities for cardiac conditions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* patients with cardiac amyloidosis, defined according to the recommendations provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data and with at least one follow-up visit.

Exclusion Criteria:

* missing data
* decline to the study participation

Where it's running

  • Fondazione Policlinico Gemelli IRCCS
    Roma, Rm, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.